TMCnet News
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)CAMBRIDGE, Mass. and BEIJING, China, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on December 31, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 44,910 American Depositary Shares to 123 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement matrial to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted share units will vest 25 percent on each anniversary of the grant, subject to the employees’ continued employment with BeiGene or one of its subsidiaries. The restricted share units are subject to the terms and conditions of BeiGene’s Amended and Restated 2018 Inducement Equity Plan and forms of award agreements covering the grants. About BeiGene i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation. Investor Contact Media Contact |